Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Nitric-oxide synthase, brain | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0027 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0017 | 0.2407 | 0.2407 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0013 | 0 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0027 | 1 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0027 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0027 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0027 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0027 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0013 | 0 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0027 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0027 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0027 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0027 | 1 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0027 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0024 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0027 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0027 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0027 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0024 | 0.7743 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0027 | 1 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0027 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0017 | 0.2407 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0027 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0027 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0027 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0027 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0014 | 0.0151 | 0.0151 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0027 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 23.5 uM | Inhibition of recombinant rat brain nNOS expressed in E. coli | ChEMBL. | 17614291 |
IC50 (binding) | = 23.5 uM | Inhibition of recombinant rat brain nNOS expressed in E. coli | ChEMBL. | 17614291 |
IC50 (binding) | = 361 uM | Inhibition of recombinant mouse macrophage iNOS expressed in E. coli | ChEMBL. | 17614291 |
IC50 (binding) | = 361 uM | Inhibition of recombinant mouse macrophage iNOS expressed in E. coli | ChEMBL. | 17614291 |
IC50 (binding) | = 1395 uM | Inhibition of recombinant bovine eNOS expressed in E. coli | ChEMBL. | 17614291 |
IC50 (binding) | = 1395 uM | Inhibition of recombinant bovine eNOS expressed in E. coli | ChEMBL. | 17614291 |
Ki (binding) | = 2.8 uM | Inhibition of recombinant rat brain nNOS expressed in E. coli | ChEMBL. | 17614291 |
Ki (binding) | = 2.8 uM | Inhibition of recombinant rat brain nNOS expressed in E. coli | ChEMBL. | 17614291 |
Ratio IC50 (binding) | = 15 | Selectivity for nNOS over iNOS | ChEMBL. | 17614291 |
Ratio IC50 (binding) | = 59 | Selectivity for nNOS over eNOS | ChEMBL. | 17614291 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.